Syndromic optic nerve hypoplasia

Syndromic optic nerve hypoplasia (ONH) refers to a group of conditions in which underdevelopment of the optic nerve occurs alongside additional systemic abnormalities, distinguishing it from isolated optic nerve hypoplasia. The most well-known form is septo-optic dysplasia (SOD, also known as de Morsier syndrome), in which optic nerve hypoplasia is associated with midline brain defects (such as absence of the septum pellucidum or corpus callosum abnormalities) and pituitary hormone deficiencies. However, syndromic ONH can also occur in the context of other developmental brain malformations and genetic syndromes. The condition primarily affects the visual system, the central nervous system, and the endocrine system. Key clinical features include reduced visual acuity (which may range from mild to severe or even blindness), nystagmus, and small optic discs detected on fundoscopic examination. Endocrine manifestations may include growth hormone deficiency, hypothyroidism, adrenal insufficiency, and diabetes insipidus due to hypothalamic-pituitary dysfunction. Neurodevelopmental delays, intellectual disability, and seizures may also be present depending on the extent of brain involvement. Some patients exhibit characteristic midline facial features or other congenital anomalies. There is no cure for syndromic optic nerve hypoplasia, and treatment is supportive and multidisciplinary. Hormone replacement therapy is critical for patients with pituitary deficiencies and can be life-saving, particularly in cases of cortisol deficiency. Visual rehabilitation, early intervention programs, and developmental support services are important components of management. Regular monitoring by ophthalmology, endocrinology, and neurology specialists is recommended. Genetic counseling may be offered, particularly when a specific genetic etiology (such as mutations in HESX1, SOX2, SOX3, or OTX2) is identified.

Common questions about Syndromic optic nerve hypoplasia